Background: Ablative surgery has been the go-to method for treating benign prostatic hyperplasia (BPH), for the better part of the past 60 years. Recent discoveries in incidence and pathogenesis as well as physiology of prostatic hyperplasia, while conventional management guidelines are put to reconsider by urologists due to recent endocrine and urology studies, which have served as the foundation for diagnosis and therapy in the past. Objective: Review literature about management options of benign prostatic hyperplasia. Methods: We scoured scholarly papers and databases including PubMed, Google Scholar, and Science Direct for information on benign prostatic hyperplasia and management between December 1999 and July 2022. However, only the latest or most comprehensive study was considered. The authors also assessed the usefulness of references taken from similar books. Documents written in languages other than English have been overlooked because of lack of funding to translate them. Unpublished articles, oral talks, conference abstracts, and dissertations were all generally agreed upon to not constitute valid scientific investigation. Conclusion: Over the course of the past ten years, a number of innovative approaches to the treatment of symptomatic BPH have come into existence. The number of possible treatments has increased, the spectrum of therapeutic choices, from careful waiting to open surgery, has broadened thanks to minimally invasive surgical techniques (MIST), novel drugs, and novel combinations of medical treatments. The range of possible symptoms is matched by the breadth of available therapies. Since deaths from BPH are uncommon, treatment typically centres on maintaining or enhancing quality of life.